Snowball logo
logo
CTKB

Cytek Biosciences, Inc. Common Stock

$4.50+$0.06  (1.35%)
Estimate
EPS
-0.58
Beta
1.17
Growth
Revenue, YoY
5.57%
Net income, YoY
-117.77%
FCF, YoY
42.21%
Forecast
P/E (FWD)
64.3
EPS (FWD)
0.07
About the company
Ticker
CTKB
ISIN
US23285D1090
Country
Other
Sector (GICS)
Healthcare
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Frequently asked questions

What sector does Cytek Biosciences, Inc. Common Stock (CTKB) operate in?

Cytek Biosciences, Inc. Common Stock belongs to the Healthcare sector and operates in the Medical Devices industry.

What is Cytek Biosciences, Inc. Common Stock (CTKB) current stock price?

As of the latest data, Cytek Biosciences, Inc. Common Stock stock price is $4.50, with a previous close of $4.44. Cytek Biosciences, Inc. Common Stock gained $0.06 in the last trading session, representing a 1.35% increase.

What is Cytek Biosciences, Inc. Common Stock (CTKB) current market capitalization?

Cytek Biosciences, Inc. Common Stock market cap is approximately 584.92 million.

What is Cytek Biosciences, Inc. Common Stock (CTKB) Earnings Per Share (EPS)?

The trailing EPS is -$0.58, and the forward EPS is $0.07.

What is Cytek Biosciences, Inc. Common Stock (CTKB) EBITDA?

Cytek Biosciences, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.38 million.

Does Cytek Biosciences, Inc. Common Stock (CTKB) pay dividends?

No. Cytek Biosciences, Inc. Common Stock does not pay a dividend.

How did Cytek Biosciences, Inc. Common Stock (CTKB) perform in its most recent earnings report?

In the last report (June 30, 2026), Cytek Biosciences, Inc. Common Stock posted an EPS surprise of -50% and a revenue surprise of 1.42%.

What is Cytek Biosciences, Inc. Common Stock (CTKB) beta (volatility) score?

Cytek Biosciences, Inc. Common Stock has a beta of 1.170, meaning its volatility is roughly in line with the market.